Template:ID-FDAPregnancyCategories
Risk Categories of Antibacterial Agents in Pregnancy Return to Top
| Antimicrobial Agent | Pregnancy Category | Drug Class |
|---|---|---|
| Penicillins | B | Antibacterial agents |
| Beta lactam/Beta lactam inhibitor | B | Antibacterial agents |
| Cephalosporins | B | Antibacterial agents |
| Aztreonam | B | Antibacterial agents |
| Meropenem | B | Antibacterial agents |
| Ertapenem | B | Antibacterial agents |
| Doripenem | B | Antibacterial agents |
| Clindamycin | B | Antibacterial agents |
| Daptomycin | B | Antibacterial agents |
| Fosfomycin | B | Antibacterial agents |
| Erythromycin | B | Antibacterial agents |
| Azithromycin | B | Antibacterial agents |
| Metronidazole | B | Antibacterial agents |
| Nitrofurantoin | B | Antibacterial agents |
| Imipenem/Cilastatin | C | Antibacterial agents |
| Chloramphenicol | C | Antibacterial agents |
| Ciprofloxacin | C | Antibacterial agents |
| Ofloxacin | C | Antibacterial agents |
| Levofloxacin | C | Antibacterial agents |
| Gatifloxacin | C | Antibacterial agents |
| Gemifloxacin | C | Antibacterial agents |
| Moxifloxacin | C | Antibacterial agents |
| Colistin | C | Antibacterial agents |
| Linezolid | C | Antibacterial agents |
| Clarithromycin | C | Antibacterial agents |
| Rifaximin | C | Antibacterial agents |
| Sulfonamides/Trimethoprim | C | Antibacterial agents |
| Telavancin | C | Antibacterial agents |
| Telithromycin | C | Antibacterial agents |
| Tinidazole | C | Antibacterial agents |
| Vancomycin | C | Antibacterial agents |
| Amikacin | D | Antibacterial agents |
| Gentamicin | D | Antibacterial agents |
| Isepamicin | D | Antibacterial agents |
| Netilmicin | D | Antibacterial agents |
| Streptomycin | D | Antibacterial agents |
| Tobramycin | D | Antibacterial agents |
| Tetracyclines | D | Antibacterial agents |
| Tigecycline | D | Antibacterial agents |
Risk Categories of Antimycobacterial Agents in Pregnancy Return to Top
| Antimicrobial Agent | Pregnancy Category | Drug Class |
|---|---|---|
| Rifabutin | B | Antimycobacterial agents |
| Capreomycin | C | Antimycobacterial agents |
| Dapsone | C | Antimycobacterial agents |
| Isoniazid | C | Antimycobacterial agents |
| Pyrazinamide | C | Antimycobacterial agents |
| Rifampin | C | Antimycobacterial agents |
| Quinine | X | Antimycobacterial agents |
| Thalidomide | X | Antimycobacterial agents |
Risk Categories of Antifungal Agents in Pregnancy Return to Top
| Antimicrobial Agent | Pregnancy Category | Drug Class |
|---|---|---|
| Amphotericin B | B | Antifungal agents |
| Anidulafungin | C | Antifungal agents |
| Caspofungin | C | Antifungal agents |
| Fluconazole | C | Antifungal agents |
| Itraconazole | C | Antifungal agents |
| Ketoconazole | C | Antifungal agents |
| Flucytosine | C | Antifungal agents |
| Micafungin | C | Antifungal agents |
| Posaconazole | C | Antifungal agents |
| Terbinafine | B | Antifungal agents |
| Voriconazole | D | Antifungal agents |
Risk Categories of Antiparasitic Agents in Pregnancy Return to Top
| Antimicrobial Agent | Pregnancy Category | Drug Class |
|---|---|---|
| Nitazoxanide | B | Antiparasitic agents |
| Praziquantel | B | Antiparasitic agents |
| Albendazole | C | Antiparasitic agents |
| Mebendazole | C | Antiparasitic agents |
| Artemether | C | Antiparasitic agents |
| Lumefantrine | C | Antiparasitic agents |
| Atovaquone | C | Antiparasitic agents |
| Proguanil | C | Antiparasitic agents |
| Chloroquine | C | Antiparasitic agents |
| Eflornithine | C | Antiparasitic agents |
| Ivermectin | C | Antiparasitic agents |
| Mefloquine | C | Antiparasitic agents |
| Pentamidine | C | Antiparasitic agents |
| Pyrimethamine | C | Antiparasitic agents |
| Quinidine | C | Antiparasitic agents |
| Miltefosine | X | Antiparasitic agents |
Risk Categories of Antiviral Agents in Pregnancy Return to Top
| Antimicrobial Agent | Pregnancy Category | Drug Class |
|---|---|---|
| Acyclovir | B | Antiviral agents |
| Atazanavir | B | Antiviral agents |
| Darunavir | B | Antiviral agents |
| Didanosine | B | Antiviral agents |
| Emtricitabine | B | Antiviral agents |
| Enfuvirtide | B | Antiviral agents |
| Etravirine | B | Antiviral agents |
| Famciclovir | B | Antiviral agents |
| Maraviroc | B | Antiviral agents |
| Nelfinavir | B | Antiviral agents |
| Ritonavir | B | Antiviral agents |
| Saquinavir | B | Antiviral agents |
| Telbivudine | B | Antiviral agents |
| Tenofovir | B | Antiviral agents |
| Valacyclovir | B | Antiviral agents |
| Abacavir | C | Antiviral agents |
| Adefovir | C | Antiviral agents |
| Amantadine | C | Antiviral agents |
| Cidofovir | C | Antiviral agents |
| Delavirdine | C | Antiviral agents |
| Entecavir | C | Antiviral agents |
| Fosamprenavir | C | Antiviral agents |
| Foscarnet | C | Antiviral agents |
| Ganciclovir | C | Antiviral agents |
| Indinavir | C | Antiviral agents |
| Interferons | C | Antiviral agents |
| Lamivudine | C | Antiviral agents |
| Lopinavir | C | Antiviral agents |
| Ritonavir | C | Antiviral agents |
| Nevirapine | C | Antiviral agents |
| Oseltamivir | C | Antiviral agents |
| Raltegravir | C | Antiviral agents |
| Rimantadine | C | Antiviral agents |
| Stavudine | C | Antiviral agents |
| Tipranavir | C | Antiviral agents |
| Valganciclovir | C | Antiviral agents |
| Zalcitabine | C | Antiviral agents |
| Zanamivir | C | Antiviral agents |
| Zidovudine | C | Antiviral agents |
| Efavirenz | D | Antiviral agents |
| Ribavirin | X | Antiviral agents |
FDA Pregnancy Categories Return to Top
| Category | Definition |
| A | Adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy |
| B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women |
| C | Animal reproduction studies have shown an adverse effect on the fetus, if there are no adequate and well-controlled studies in humans, and if the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks |
| D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks |
| X | Studies in animals or humans have demonstrated fetal abnormalities or if there is positive evidence of fetal risk based on adverse reaction reports from investigational or marketing experience, or both, and the risk of the use of the drug in a pregnant woman clearly outweighs any possible benefit |